Healthcare -
Biotechnology - NASDAQ - GB
$ 2.39
-8.63 %
$ 371 M
Market Cap
-7.77
P/E
INCOME STATEMENT
EFFICIENCY
Earnings Waterfall
Mereo BioPharma Group plc
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 47.4 M |
| Operating Income | -47.4 M |
| Other Expenses | -4.11 M |
| Net Income | -43.3 M |
Income Statement
Millions
| Dec-2024 | Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Revenue | 0 | 10.0 | 1.5 | 36.5 | 0.4 | (0.1) | 0 | (3.3) | 0 |
| GROSS PROFIT | |||||||||
| Cost Of Revenue | 0 | 2.6 | 0.9 | 17.9 | 16.3 | 23.6 | 22.7 | 34.6 | 24.6 |
| Gross Profit | 0 | 7.4 | 0.6 | 18.6 | (16.0) | (23.7) | (22.7) | (37.9) | (24.6) |
| OPERATING INCOME | |||||||||
| Operating Expenses | 47.4 | 35.8 | 44.5 | 39.5 | 21.2 | 15.9 | 12.5 | 10.7 | 11.6 |
| Selling, General and Administrative Expenses | 26.4 | 18.4 | 19.5 | 15.9 | 21.2 | 15.9 | 12.5 | 10.7 | 11.6 |
| Research and Development Expenses | 20.9 | 17.4 | 25.0 | 23.6 | (16.3) | (23.6) | 22.7 | 34.6 | 24.6 |
| Operating Income | (47.4) | (28.4) | (43.6) | (20.9) | (37.6) | (39.5) | (35.2) | (45.3) | (36.2) |
| PRE-TAX INCOME | |||||||||
| Interest Income Expense | (1.4) | 2.9 | 3.4 | 4.0 | 6.4 | 3.5 | 2.4 | 1.1 | 0.2 |
| Total Other Income | 4.1 | (1.6) | 7.5 | 40.2 | (129.3) | (1.6) | (2.1) | (1.6) | 2.5 |
| Pre-Tax Income | (43.3) | (30.0) | (36.1) | 14.2 | (166.4) | (41.1) | (37.3) | (47.0) | (33.7) |
| NET INCOME | |||||||||
| Tax Provision | 18.2 K | (0.5) | (1.9) | 1.5 | (2.8) | (6.3) | (5.3) | (8.2) | (5.3) |
| Net Income | (43.3) | (29.5) | (34.2) | 12.7 | (163.6) | (34.8) | (32.0) | (38.8) | (28.4) |
| EPS | 0.29 | 1.1 K | 1.75 K | 750 | 16.5 K | 12.9 K | 14.4 K | 19 K | 19.6 K |